Mississauga, ON
Canadian affiliate of Ares-Serono International. S. A. Biotechnology company specializing in R&D, marketing, sales and distribution of biopharmaceutical and diagnostic products. Competes in reproductive medicine, oncology, endocrine and immunology specialties.
15-20 studies underway with recombinant fertility and growth hormones, recombinant interferon-beta, IL-6, somatostatin, recombinant tumor necrosis factor binding protein. Indications:
male/female infertility, multiple sclerosis, HIV muscle wasting, gastrointestinal disorders, chronic renal failure.
R&D focusing on reproductive medicine, immunology/oncology, CNS neurological, endocrine, metabolic and rheumatology specialties.
200-2695 North Sheridan Way
Mississauga, ON L5K 2N6
CA
200-2695 North Sheridan Way
Mississauga, ON L5K 2N6
CA
Legal Name: Serono Canada Inc.
Number of Employees: 18
CA
Title: Executive Administrator
Area of Responsibility: Administrative Services
Phone: Show phone
Fax: Show fax
Email: Show email
Title: Manager
Area of Responsibility: Domestic Sales & Marketing
Phone: Show phone
Fax: Show fax
Email: Show email
FertinormHP (Urofollitropin) followed by chorionic gonadotrophin (hCG) stimulation of follicular development and ovulation.
(Sermorelin Acetate) For the evaluation of short children whose height is at least 2 standard deviations below the mean height for their chronological age and sex, presenting low basal serum levels of IGF-1 and IFG-1-BP3 and who have failed to pass the exercise or the sleep test.
PROFASI HP (chorionic gonadotropin) is indicated for ovulation induction; treatment of abortion (habitual); infrequent scanty bleeding; functional sterility; prepubertal cryptorchidism;
delayed adolescence; dwarfish (pituitary); hypogonadotropic eunuchoidism; selected cases of hypogonadotropic hypogonadism
(Gonadorelin Acetate) As a diagnostic test for the evaluation of the pituitary component of the hypothalamus-pituitary-gonad axis.
For the long term treatment of patients with growth failure due to inadequate secretion of normal endogenous growth hormone. Other causes for growth failure should be ruled out.
(Clomiphene Citrate) in the treatment of ovulatory failure in patients desiring pregnancy, whose husbands have adequate sperm and who have potentially functional hypothalamic-hypophyseal ovarian systems and adequate endogenous estrogen.
For the symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of the condition may be considered, if necessary, once initial control has been established.
541710